HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Oxymetazoline Hydrochloride

HCID 66259
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
2315-02-8
Standard SMILES
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
InChIKey
BEEDODBODQVSIM-UHFFFAOYSA-N
Molecular formula
C16H24N2O.ClH
Average molar mass
296.83 g/mol
Monoisotopic mass
296.1655411

Overview

Oxymetazoline hydrochloride is a hydrochloride salt resulting from the reaction of equimolar quantities of oxymetazoline and hydrogen chloride. A direct-acting sympathomimetic with marked alpha-adrenergic activity, it is a vasoconstrictor that is used to relieve nasal congestion. It has a role as a sympathomimetic agent, an alpha-adrenergic agonist, a vasoconstrictor agent and a nasal decongestant. It contains an oxymetazoline(1+).

Names & identifiers

Preferred name
Oxymetazoline Hydrochloride
IUPAC
6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol;hydrochloride

Names & synonyms

Oxymetazoline hydrochloride2315-02-8Oxymetazoline HClOcuclearAfrazineNostrillaRhofadeSch 9384Visine L.R.Vicks SinexAnefrin nasalK89MJ0S5VY
Show more names
NSC-757254UPNEEQAgn-199201SCH-9384CHEBI:7863DTXSID801777292-(4-t-Butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazolinium chloride2,6-Dimethyl-2-(4-tertiarybutyl-3-hydroxyphenyl)methylimidazoline hydrochloride

Database identifiers

CAS
2315-02-8
PubChem CID
66259
DTXSID
DTXSID80177729
ChEMBL
CHEMBL1200791
ChEBI
CHEBI:7863
UNII
K89MJ0S5VY
EC Number
219-015-0

Properties

Computed structural properties

Topological polar surface area
44.6 Ų
Hydrogen bond donors
3
Hydrogen bond acceptors
2
Rotatable bonds
3
Heavy atoms
20
Formal charge
0
Complexity
345

Experimental & physicochemical properties

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section169.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H300 (75%): Fatal if swallowed [Danger Acute toxicity, oral]

P260, P264, P264+P265, P270, P271, P273, P280, P284, P301+P316, P304+P340, P305+P354+P338, P316, P317, P319, P320, P321, P330, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 148 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

Chemical: Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-, monohydrochloride

Oxymetazoline hydrochloride: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-, monohydrochloride: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 1 (75%)

Chemistry & industry

Pharmacology

FDA Pharmacological Classification · 6 items

ALLERGY SINUS

Increased Sympathetic Activity [PE]; Vasoconstriction [PE]; Imidazolines [CS]; Vasoconstrictor [EPC]

NASAL OXYMETAZOLINE HCL

Increased Sympathetic Activity [PE]; Vasoconstriction [PE]; Imidazolines [CS]; Vasoconstrictor [EPC]

OXYMETAZOLINE HCL

Increased Sympathetic Activity [PE]; Imidazolines [CS]; Vasoconstriction [PE]; Vasoconstrictor [EPC]

MeSH Pharmacological Classification · 3 items

Drugs that selectively bind to and activate alpha adrenergic receptors.

Drugs that mimic the effects of stimulating postganglionic adrenergic sympathetic nerves. Included here are drugs that directly stimulate adrenergic receptors and drugs that act indirectly by provoking the release of adrenergic transmitters.

Drugs designed to treat inflammation of the nasal passages, generally the result of an infection (more often than not the common cold) or an allergy related condition, e.g., hay fever. The inflammation involves swelling of the mucous membrane that lines the nasal passages and results in inordinate mucus production. The primary class of nasal decongestants are vasoconstrictor agents. (From PharmAssist, The Family Guide to Health and Medicine, 1993)

Related reactions

1 records
New reaction record
HRID 2191206 reaction equation
HRID 2191206As reactant

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes